Research
Cellular
People with MASH and clinically significant fibrosis are at risk of progressing to cirrhosis and hepatocellular carcinoma.
Monitoring and intervention are crucial for patients with MASH and fibrosis.
StrongSupportsmedium confidence
People with MASH and clinically significant fibrosis (stage F2/F3) are 'at risk' of progressing to cirrhosis and hepatocellular carcinoma.
Why this rating
The claim is based on established clinical knowledge.
Source
Safety Choice Drivers of the Coming Treatment Options for Non‐Cirrhotic Metabolic Steatohepatitis
Alessandra Mangia et al. · Liver International · 2025
DOI 10.1111/liv.70271
otherCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →